TriSalus Life Sciences Inc (NAS:TLSI)

Q1 2026 TriSalus Life Sciences Inc Earnings Call Transcript

May 12, 2026 / 08:30 PM GMT

Release Date Price: $4.56 (+0.44%)

Transcript 10-Q8-K

Key Points

Positve

TriSalus Life Sciences Inc (TLSI) has significantly expanded its commercial organization, positioning itself for multi-year growth.
The company published a landmark real-world evidence study demonstrating the clinical and economic benefits of its PEDD technology, including fewer complications and hospitalizations.
Gross margins improved to 86% from 84% in the prior-year period, driven by lower average unit costs and continuous manufacturing improvements.
The company is actively generating new clinical evidence with 10 active studies across 24 clinical sites, enhancing its data-driven approach.
TriSalus Life Sciences Inc (TLSI) has a strong cash position of $56.6 million, fully funding its strategic growth plan.

Negative

Revenue for the first quarter decreased to $8.9 million from $9.2 million in the prior-year period due to disruptions from the commercial expansion.
The company revised its full-year 2026 revenue guidance to $54 million to $57 million, down from previous expectations, due to lower Q1 revenues and delayed FDA clearance for TriNav Advance.
Net operating loss increased to $8.4 million from $7.3 million in the prior-year period, reflecting lower revenue and increased sales and marketing investments.
The FDA review of TriNav Advance is running approximately five months past the expected timeline, impacting revenue expectations.
The expansion of the sales force caused short-term disruptions, affecting 40% of sales territories and requiring time for new representatives to ramp up.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TLSI.OQ - TriSalus Life Sciences Inc
Q1 2026 TriSalus Life Sciences Inc Earnings Call
May 12, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to the TriSalis Life Sciences First Quarter 2026 Earnings Conference Call. All participants are currently in a listen-only mode. Following management's prepared remarks, we will hold a question-and-answer session. As a reminder, this call is being recorded for replay purposes. I will now turn the call over to Jeremy Pfeffer, Managing. Director with LifeSci Advisors. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and thank you all for joining us today.

With me from Trisalis Life Sciences are Mary

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.